UPC vs. GRTX, CMMB, MTEM, ATHE, NCNA, ADXN, AEZS, GHSI, MBRX, and GRAY
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Galera Therapeutics (GRTX), Chemomab Therapeutics (CMMB), Molecular Templates (MTEM), Alterity Therapeutics (ATHE), NuCana (NCNA), Addex Therapeutics (ADXN), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and Graybug Vision (GRAY). These companies are all part of the "pharmaceutical preparations" industry.
Galera Therapeutics (NASDAQ:GRTX) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
Galera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
Universe Pharmaceuticals has higher revenue and earnings than Galera Therapeutics.
Galera Therapeutics received 50 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
In the previous week, Galera Therapeutics had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for Galera Therapeutics and 1 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.54 beat Galera Therapeutics' score of 0.00 indicating that Galera Therapeutics is being referred to more favorably in the media.
50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Galera Therapeutics beats Universe Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
